Loading…
Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies
Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing...
Saved in:
Published in: | International journal of molecular sciences 2019-03, Vol.20 (6), p.1449 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783 |
---|---|
cites | cdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783 |
container_end_page | |
container_issue | 6 |
container_start_page | 1449 |
container_title | International journal of molecular sciences |
container_volume | 20 |
creator | Horton, Julie L Virag, Jitka |
description | Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed. |
doi_str_mv | 10.3390/ijms20061449 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_5ef43e8150a0437abf7123a36513f94b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_5ef43e8150a0437abf7123a36513f94b</doaj_id><sourcerecordid>2197887905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</originalsourceid><addsrcrecordid>eNpdkktvEzEURkcIREthxxqNxIYFAb9mPN4gVVELkVohQbq2rl-JI2ccbA-iC_57naZUKSu_zj36rnWb5i1GnygV6LPfbDNBqMeMiWfNKWaEzOqRPz_anzSvct4gRCjpxMvmhCKBBOX9afP3Jts2uvZ6CsU70CUmD6FdJgtla8eS2xLbc2OSzXW7tu18DSHYcXVftUww5gDFj6v24s_OJr-vqfXXt1FDMnvVYnSQdGl_WDPp4uPY_iwJil15m183LxyEbN88rGfNzeXFcv5tdvX962J-fjXTjA9lxjAo7JhSRKHOadVRrZygVhlGhHHUoJ71ApjRrmeCDazrOMfEdQ44F3ygZ83i4DURNnJXY0K6lRG8vL-IaSUhFa-DlZ11jNoBdwgQoxyUqyYKtO8wdYKp6vpycO0mtbVG14YThCfSpy-jX8tV_C17xjGj-zAfHgQp_ppsLnLrs7YhwGjjlCXBNfLABeoq-v4_dBOnNNavkoTSCg696Cv18UDpFHNO1j2GwUjuZ0Qez0jF3x038Aj_Gwp6B8Jzud4</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2332198696</pqid></control><display><type>article</type><title>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</title><source>Open Access: PubMed Central</source><source>ProQuest - Publicly Available Content Database</source><creator>Horton, Julie L ; Virag, Jitka</creator><creatorcontrib>Horton, Julie L ; Virag, Jitka</creatorcontrib><description>Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms20061449</identifier><identifier>PMID: 30909376</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Animals ; cardioprotection ; Cardiotonic Agents ; Combined Modality Therapy ; Diabetes ; Disease Management ; Economic impact ; Ephrin-A1 - genetics ; Ephrin-A1 - metabolism ; Ephrin-A1 - therapeutic use ; Ephrin-A1 - ultrastructure ; ephrinA1 ; Heart attacks ; Heart failure ; Humans ; Immunoglobulin Fc Fragments - therapeutic use ; Immunoglobulin Fc Fragments - ultrastructure ; Ischemia ; Ligands ; Mortality ; Myocardial infarction ; Myocardial Infarction - diagnosis ; Myocardial Infarction - etiology ; Myocardial Infarction - metabolism ; Myocardial Infarction - therapy ; Oxidation ; Patients ; Recombinant Fusion Proteins - therapeutic use ; Recombinant Fusion Proteins - ultrastructure ; Reperfusion ; Review ; Scars ; Socioeconomic factors ; therapeutic strategies ; Translational Research, Biomedical ; Treatment Outcome</subject><ispartof>International journal of molecular sciences, 2019-03, Vol.20 (6), p.1449</ispartof><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</citedby><cites>FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</cites><orcidid>0000-0003-3321-9861</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2332198696/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2332198696?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30909376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Horton, Julie L</creatorcontrib><creatorcontrib>Virag, Jitka</creatorcontrib><title>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.</description><subject>Animals</subject><subject>cardioprotection</subject><subject>Cardiotonic Agents</subject><subject>Combined Modality Therapy</subject><subject>Diabetes</subject><subject>Disease Management</subject><subject>Economic impact</subject><subject>Ephrin-A1 - genetics</subject><subject>Ephrin-A1 - metabolism</subject><subject>Ephrin-A1 - therapeutic use</subject><subject>Ephrin-A1 - ultrastructure</subject><subject>ephrinA1</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Immunoglobulin Fc Fragments - therapeutic use</subject><subject>Immunoglobulin Fc Fragments - ultrastructure</subject><subject>Ischemia</subject><subject>Ligands</subject><subject>Mortality</subject><subject>Myocardial infarction</subject><subject>Myocardial Infarction - diagnosis</subject><subject>Myocardial Infarction - etiology</subject><subject>Myocardial Infarction - metabolism</subject><subject>Myocardial Infarction - therapy</subject><subject>Oxidation</subject><subject>Patients</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Recombinant Fusion Proteins - ultrastructure</subject><subject>Reperfusion</subject><subject>Review</subject><subject>Scars</subject><subject>Socioeconomic factors</subject><subject>therapeutic strategies</subject><subject>Translational Research, Biomedical</subject><subject>Treatment Outcome</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkktvEzEURkcIREthxxqNxIYFAb9mPN4gVVELkVohQbq2rl-JI2ccbA-iC_57naZUKSu_zj36rnWb5i1GnygV6LPfbDNBqMeMiWfNKWaEzOqRPz_anzSvct4gRCjpxMvmhCKBBOX9afP3Jts2uvZ6CsU70CUmD6FdJgtla8eS2xLbc2OSzXW7tu18DSHYcXVftUww5gDFj6v24s_OJr-vqfXXt1FDMnvVYnSQdGl_WDPp4uPY_iwJil15m183LxyEbN88rGfNzeXFcv5tdvX962J-fjXTjA9lxjAo7JhSRKHOadVRrZygVhlGhHHUoJ71ApjRrmeCDazrOMfEdQ44F3ygZ83i4DURNnJXY0K6lRG8vL-IaSUhFa-DlZ11jNoBdwgQoxyUqyYKtO8wdYKp6vpycO0mtbVG14YThCfSpy-jX8tV_C17xjGj-zAfHgQp_ppsLnLrs7YhwGjjlCXBNfLABeoq-v4_dBOnNNavkoTSCg696Cv18UDpFHNO1j2GwUjuZ0Qez0jF3x038Aj_Gwp6B8Jzud4</recordid><startdate>20190322</startdate><enddate>20190322</enddate><creator>Horton, Julie L</creator><creator>Virag, Jitka</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3321-9861</orcidid></search><sort><creationdate>20190322</creationdate><title>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</title><author>Horton, Julie L ; Virag, Jitka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>cardioprotection</topic><topic>Cardiotonic Agents</topic><topic>Combined Modality Therapy</topic><topic>Diabetes</topic><topic>Disease Management</topic><topic>Economic impact</topic><topic>Ephrin-A1 - genetics</topic><topic>Ephrin-A1 - metabolism</topic><topic>Ephrin-A1 - therapeutic use</topic><topic>Ephrin-A1 - ultrastructure</topic><topic>ephrinA1</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Immunoglobulin Fc Fragments - therapeutic use</topic><topic>Immunoglobulin Fc Fragments - ultrastructure</topic><topic>Ischemia</topic><topic>Ligands</topic><topic>Mortality</topic><topic>Myocardial infarction</topic><topic>Myocardial Infarction - diagnosis</topic><topic>Myocardial Infarction - etiology</topic><topic>Myocardial Infarction - metabolism</topic><topic>Myocardial Infarction - therapy</topic><topic>Oxidation</topic><topic>Patients</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Recombinant Fusion Proteins - ultrastructure</topic><topic>Reperfusion</topic><topic>Review</topic><topic>Scars</topic><topic>Socioeconomic factors</topic><topic>therapeutic strategies</topic><topic>Translational Research, Biomedical</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Horton, Julie L</creatorcontrib><creatorcontrib>Virag, Jitka</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest_Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest - Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Horton, Julie L</au><au>Virag, Jitka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-03-22</date><risdate>2019</risdate><volume>20</volume><issue>6</issue><spage>1449</spage><pages>1449-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>30909376</pmid><doi>10.3390/ijms20061449</doi><orcidid>https://orcid.org/0000-0003-3321-9861</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1422-0067 |
ispartof | International journal of molecular sciences, 2019-03, Vol.20 (6), p.1449 |
issn | 1422-0067 1661-6596 1422-0067 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_5ef43e8150a0437abf7123a36513f94b |
source | Open Access: PubMed Central; ProQuest - Publicly Available Content Database |
subjects | Animals cardioprotection Cardiotonic Agents Combined Modality Therapy Diabetes Disease Management Economic impact Ephrin-A1 - genetics Ephrin-A1 - metabolism Ephrin-A1 - therapeutic use Ephrin-A1 - ultrastructure ephrinA1 Heart attacks Heart failure Humans Immunoglobulin Fc Fragments - therapeutic use Immunoglobulin Fc Fragments - ultrastructure Ischemia Ligands Mortality Myocardial infarction Myocardial Infarction - diagnosis Myocardial Infarction - etiology Myocardial Infarction - metabolism Myocardial Infarction - therapy Oxidation Patients Recombinant Fusion Proteins - therapeutic use Recombinant Fusion Proteins - ultrastructure Reperfusion Review Scars Socioeconomic factors therapeutic strategies Translational Research, Biomedical Treatment Outcome |
title | Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T05%3A09%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Multifactorial%20Treatments%20to%20Address%20the%20Challenge%20of%20Translating%20Experimental%20Myocardial%20Infarct%20Reduction%20Strategies&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Horton,%20Julie%20L&rft.date=2019-03-22&rft.volume=20&rft.issue=6&rft.spage=1449&rft.pages=1449-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms20061449&rft_dat=%3Cproquest_doaj_%3E2197887905%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-41ab1f4bb2b05fcb53cbf93ebd429df3d06469a4dcf649484557712f5fa779783%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2332198696&rft_id=info:pmid/30909376&rfr_iscdi=true |